919 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
TEVA Teva Pharmaceutical Industries Limited $23.43 $23.86B N/A
Article Searches
AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia http://www.zacks.com/stock/news/322740/abbvie-gets-fda-nod-for-venclexta-label-expansion-in-leukemia?cid=CS-ZC-FT-322740 Sep 12, 2018 - AbbVie (ABBV) gets FDA approval to include MRD-negativity (undetectable disease) data from phase III MURANO study on the label of Venclexta.
New Marijuana Stocks? & Earnings from ORCL and FDX | Free Lunch http://www.zacks.com/stock/news/323412/new-marijuana-stocks-earnings-from-orcl-and-fdx-free-lunch?cid=CS-ZC-FT-323412 Sep 17, 2018 - Ryan McQueeney touches on the trade war's latest tariff threats and a key FDA approval for Teva Pharmaceuticals. He also highlights two surprising companies which might have a chance to profit from the marijuana boom. Later, Ryan previews Oracle and FedEx's earnings reports.
AstraZeneca's Fasenra Long-Term Asthma Study Data Positive http://www.zacks.com/stock/news/323891/astrazenecas-fasenra-long-term-asthma-study-data-positive?cid=CS-ZC-FT-323891 Sep 19, 2018 - AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.
Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality http://www.zacks.com/stock/news/325483/eli-lilly-lly-gets-fda-nod-for-migraine-drug-emgality?cid=CS-ZC-FT-325483 Sep 28, 2018 - Eli Lilly's (LLY) CGRP antibody Emgality injection gains an FDA approval for the preventive treatment of migraine in adults.
Why Teva Pharmaceutical Industries Ltd. (TEVA) is Poised to Beat Earnings Estimates Again http://www.zacks.com/stock/news/325870/why-teva-pharmaceutical-industries-ltd-teva-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-325870 Oct 02, 2018 - Teva Pharmaceutical Industries Ltd. (TEVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing http://www.zacks.com/stock/news/327546/teva-gets-fda-committee-nod-for-rituxan-biosimilar-filing?cid=CS-ZC-FT-327546 Oct 11, 2018 - Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.
Teva (TEVA) to Report Q3 Earnings: What's in the Cards? http://www.zacks.com/stock/news/332222/teva-teva-to-report-q3-earnings-whats-in-the-cards?cid=CS-ZC-FT-332222 Oct 29, 2018 - While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
What's in the Cards for Amarin (AMRN) This Earnings Season? http://www.zacks.com/stock/news/332215/whats-in-the-cards-for-amarin-amrn-this-earnings-season?cid=CS-ZC-FT-332215 Oct 29, 2018 - Amarin (AMRN) is scheduled to release third-quarter earnings on Nov 1.
Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise http://www.zacks.com/stock/news/334690/teva-teva-q3-earnings-beat-2018-eps-view-up-shares-rise?cid=CS-ZC-FT-334690 Nov 02, 2018 - Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.
Lilly (LLY) Tops Q3 Earnings, Lifts 2018 Outlook, Stock Up http://www.zacks.com/stock/news/335522/lilly-lly-tops-q3-earnings-lifts-2018-outlook-stock-up?cid=CS-ZC-FT-335522 Nov 06, 2018 - Eli Lilly (LLY) beats estimates for earnings but misses the same for sales. The company raises its previously issued outlook for adjusted earnings. Stock rises in pre-market trading.
<<<Page 86>